An easy-to-miss footnote to FDA’s recent 510(k) program draft guidance is attracting the attention of some industry experts as a potential overstepping of agency authority.
The language in question, tucked into the 40-plus-page document issued last month, could create a new requirement for nonclinical studies performed in support of 510(k)s, stakeholders say.